Who Owns Coloplast Company?

Coloplast Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Coloplast?

Delving into Coloplast SWOT Analysis, a global leader in medical devices, reveals a complex ownership structure that significantly impacts its strategic decisions. Understanding who owns Coloplast is essential for investors and stakeholders alike, as it shapes the company's long-term vision and operational priorities. The recent establishment of a new holding company by its largest shareholder underscores the importance of ownership in ensuring stability and future growth for this major player in the healthcare industry.

From its humble beginnings in 1957, Coloplast company has grown into a multinational corporation with a substantial market share. The Coloplast history is intertwined with its ownership, from the founding by Aage and Johanne Louis-Hansen to its current structure. As a publicly traded company, understanding the nuances of Coloplast ownership, including its major shareholders and the influence they wield, is crucial for anyone seeking to understand its future trajectory and make informed decisions about Coloplast company stock.

The story of Coloplast, a leading medical device company, began with a personal need. Nurse Elise Sørensen's innovative idea for an ostomy bag set the stage for the company's founding. This concept was the catalyst for the creation of a company dedicated to improving the lives of individuals with intimate healthcare needs.

In 1957, civil engineer Aage Louis-Hansen and his wife, nurse Johanne Louis-Hansen, established Coloplast in Denmark. While the exact initial ownership breakdown isn't publicly available, the Louis-Hansen family has played a crucial role in the company's trajectory. Their early involvement was critical in shaping the company's direction and values.

The founders' commitment to addressing specific healthcare needs has been a core principle since the beginning. This focus on innovation and patient care has been a constant throughout Coloplast's history, influencing its product development and overall mission. The company's structure was designed to ensure the founders' long-term vision was maintained.

The Founders

Coloplast was founded by Aage Louis-Hansen and Johanne Louis-Hansen, inspired by Elise Sørensen's invention. The founders' background in engineering and nursing provided a unique perspective. Their combined expertise was instrumental in developing the initial products.

Early Ownership

The Louis-Hansen family has held a significant ownership stake since the company's inception. The Aage & Johanne Louis-Hansen Foundation is a major shareholder. This long-term commitment has ensured stability and a consistent vision.

Family Influence

Niels Peter Louis-Hansen, son of the founders, currently owns 20% of the company. He also serves as Deputy Chairman. This continued family involvement underscores the founders' enduring impact.

Share Structure

A dual-class share structure was established early on to protect the founders' control. Class A shares have ten votes per share, while Class B shares have one vote. This structure ensured the founders' long-term vision.

Mission and Values

The founders' vision of addressing intimate healthcare needs is central to Coloplast's mission. The company's early development was deeply influenced by this focus. This focus continues to drive product innovation and patient care.

Early Backers

The Aage & Johanne Louis-Hansen Foundation was a key early backer of Coloplast. The foundation remains a major shareholder. This support helped fuel the company's growth.

Key Takeaways on Coloplast Ownership

Understanding the ownership structure of Coloplast provides insights into its strategic direction and long-term goals. The Louis-Hansen family's continued involvement and the dual-class share structure have ensured a consistent focus on innovation and patient needs. For more details, check out the Marketing Strategy of Coloplast.

• The founders, Aage and Johanne Louis-Hansen, established the company in 1957.
• Niels Peter Louis-Hansen, son of the founders, holds a 20% stake and serves as Deputy Chairman.
• The Aage & Johanne Louis-Hansen Foundation is a significant shareholder.
• A dual-class share structure reinforces the founders' control.

Coloplast SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of the Coloplast company is primarily influenced by its listing on Nasdaq Copenhagen (COLO B). The ownership structure has evolved over time, but the founding family maintains a significant controlling stake. This structure has allowed for a long-term strategic approach, as highlighted by the company's leadership.

A key aspect of the ownership structure is the dual-class share system, which allows the founding family to retain considerable control. This structure has been a consistent feature, ensuring stability in strategic decision-making. The evolution of the ownership reflects the company's growth and its continued commitment to its long-term vision.

As of May 2025, institutional investors hold a significant portion of the shares, with BlackRock, Inc. owning 2.59% and The Vanguard Group, Inc. holding 2.39% as of April 2025. Private companies collectively own 30.4%, and the general public holds approximately 40.2% of the shares. This distribution illustrates a blend of family control, institutional investment, and public ownership, reflecting the 's market position and investor base.

Key Ownership Facts

The founding family, through various holdings, maintains significant control over the company. Institutional investors hold a substantial portion of the shares, reflecting the company's appeal to a broad investor base.

• Niels Peter Louis-Hansen, through his holdings, controls a significant percentage of both share capital and voting rights.
• Institutional investors, including BlackRock and The Vanguard Group, are major stakeholders.
• The general public holds a considerable portion of the shares, reflecting the company's public listing.
• The dual-class share structure has historically allowed for a stable and long-term strategic approach.

Coloplast PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors of the Coloplast company is integral to its governance, with representation from significant shareholders and independent members. Niels Peter Louis-Hansen serves as Deputy Chairman, reflecting the enduring influence of the founding family. The board consists of seven active members, including Niels Peter Louis-Hansen, Birgitte Nielsen, Jette Nygaard-Andersen, Thomas Tærsbøl Barfod, Carsten Hellmann, Roland Vendelbo Pedersen, and Jørgen Tang-Jensen, all identified as independent board members.

The board's composition and the ownership structure are key factors in understanding the company's strategic direction and operational oversight. The presence of independent members ensures a balance of perspectives, while the family's continued involvement, through Niels Peter Louis-Hansen, provides stability and a long-term vision, which is crucial for sustained growth and innovation within the healthcare sector. Understanding the dynamics of the board is essential for anyone interested in the Coloplast company.

Coloplast operates with a dual-class share structure. Class A shares offer ten votes per share, while Class B shares grant one vote per share. This structure allows the Louis-Hansen family, through Coloplast Holding ApS, to maintain significant control. As of August 2023, Coloplast Holding ApS held 51.36% of the voting rights with 29.49% of the share capital. Niels Peter Louis-Hansen directly and indirectly held 56.54% of the voting rights with 32.76% of the share capital. This ownership model ensures a stable, long-term perspective, as highlighted by Lars Rasmussen, Chairman of the Coloplast Board of Directors, in June 2023. To delve deeper into the financial aspects, consider exploring Revenue Streams & Business Model of Coloplast.

Ownership and Control

The Louis-Hansen family, through Coloplast Holding ApS, maintains significant voting power despite holding a minority of the total share capital.

• Dual-class share structure gives Class A shares ten votes per share.
• Coloplast Holding ApS held 51.36% of voting rights as of August 2023.
• Niels Peter Louis-Hansen held 56.54% of the voting rights directly and indirectly.
• This structure ensures long-term stability and family influence.

Coloplast Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, strategic acquisitions have significantly influenced the ownership and financial landscape of the Coloplast company. The acquisition of Atos Medical in November 2021 for approximately $2.5 billion and Kerecis in 2023 for around $1.3 billion, demonstrates the company's expansion into high-growth segments. The Kerecis acquisition, which involved a capital increase, is projected to contribute about 1%-point to group organic growth as of FY 2024/25. These moves are part of a broader strategy to enhance the company's market position.

In June 2023, the establishment of a new holding company by Niels Peter Louis-Hansen and the Aage & Johanne Louis-Hansen Foundation aimed to secure long-term ownership. This holding company now holds roughly 30% of the company's capital and controls approximately 52% of the votes, reinforcing family influence despite increasing institutional ownership. As of May 2025, individual investors account for 40% of Coloplast's ownership, while private companies hold 30%, shaping the dynamics of who owns Coloplast.

Coloplast maintains a dividend policy targeting a 60-80% payout ratio of net profit and utilizes share buybacks. The company announced an interim dividend of DKK 5.00 per share for H1 2024/25, totaling DKK 1,126 million. Recent developments include a voluntary product recall in the Bladder Health and Surgery segment in Q1 2024/25, impacting Interventional Urology growth. In December 2024, the Skin Care portfolio was divested to streamline operations, which will reduce reported revenue for FY 2024/25 by approximately DKK 350 million.

Ownership Structure

Individual investors hold a significant portion of Coloplast's ownership. Private companies and family holdings also play key roles. The family's influence is maintained through a holding company.

Financial Performance

The company has revised its financial guidance for the fiscal year 2024/25. Organic growth is expected around 7%. The EBIT margin before special items is projected between 27-28%.

Strategic Moves

Coloplast has made strategic acquisitions, such as Atos Medical and Kerecis. The company divested its Skin Care portfolio. These moves are designed to improve profitability.

Dividend and Buybacks

Coloplast distributes excess liquidity through dividends and share buybacks. The target payout ratio is between 60-80% of net profit. An interim dividend was announced for H1 2024/25.

Coloplast Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs